144 related articles for article (PubMed ID: 22173501)
1. Relationship between aberrant methylation of FAS promoter and biological behavior of bladder urothelial carcinoma.
Li W; Xia D; Wang Y; Li Y; Xue Y; Wu X; Ye Z
J Huazhong Univ Sci Technolog Med Sci; 2011 Dec; 31(6):794-798. PubMed ID: 22173501
[TBL] [Abstract][Full Text] [Related]
2. Hypermethylation of the tumor necrosis factor receptor superfamily 6 (APT1, Fas, CD95/Apo-1) gene promoter at rel/nuclear factor kappaB sites in prostatic carcinoma.
Santourlidis S; Warskulat U; Florl AR; Maas S; Pulte T; Fischer J; Müller W; Schulz WA
Mol Carcinog; 2001 Sep; 32(1):36-43. PubMed ID: 11568974
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of opioid binding protein/cell adhesion molecule-like promoter methylation in bladder carcinoma.
Duarte-Pereira S; Paiva F; Costa VL; Ramalho-Carvalho J; Savva-Bordalo J; Rodrigues A; Ribeiro FR; Silva VM; Oliveira J; Henrique R; Jerónimo C
Eur J Cancer; 2011 May; 47(7):1106-14. PubMed ID: 21273058
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic inactivation of ST6GAL1 in human bladder cancer.
Antony P; Rose M; Heidenreich A; Knüchel R; Gaisa NT; Dahl E
BMC Cancer; 2014 Dec; 14():901. PubMed ID: 25465919
[TBL] [Abstract][Full Text] [Related]
5. Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma.
Dhawan D; Hamdy FC; Rehman I; Patterson J; Cross SS; Feeley KM; Stephenson Y; Meuth M; Catto JW
J Pathol; 2006 Jul; 209(3):336-43. PubMed ID: 16639696
[TBL] [Abstract][Full Text] [Related]
6. Promoter hypomethylation as potential confounder of Ras gene overexpression and their clinical significance in subsets of urothelial carcinoma of bladder.
Tripathi K; Goel A; Singhai A; Garg M
Mol Biol Rep; 2021 Mar; 48(3):2183-2199. PubMed ID: 33620658
[TBL] [Abstract][Full Text] [Related]
7. Oxidative stress induces hypomethylation of LINE-1 and hypermethylation of the RUNX3 promoter in a bladder cancer cell line.
Wongpaiboonwattana W; Tosukhowong P; Dissayabutra T; Mutirangura A; Boonla C
Asian Pac J Cancer Prev; 2013; 14(6):3773-8. PubMed ID: 23886181
[TBL] [Abstract][Full Text] [Related]
8. The role of aberrant promoter hypermethylation of DACT1 in bladder urothelial carcinoma.
Cheng H; Deng Z; Wang Z; Zhang W; Su J
J Biomed Res; 2012 Sep; 26(5):319-24. PubMed ID: 23554767
[TBL] [Abstract][Full Text] [Related]
9. Promoter hypermethylation of the 14-3-3 sigma, SYK and CAGE-1 genes is related to the various phenotypes of urinary bladder carcinomas and associated with progression of transitional cell carcinomas.
Kunze E; Wendt M; Schlott T
Int J Mol Med; 2006 Oct; 18(4):547-57. PubMed ID: 16964403
[TBL] [Abstract][Full Text] [Related]
10. Biological significance of TERT promoter mutation in papillary urothelial neoplasm of low malignant potential.
Wang CC; Huang CY; Jhuang YL; Chen CC; Jeng YM
Histopathology; 2018 Apr; 72(5):795-803. PubMed ID: 29193225
[TBL] [Abstract][Full Text] [Related]
11. Clinical performance and utility of a noninvasive urine-based methylation biomarker: TWIST1/Vimentin to detect urothelial carcinoma of the bladder.
Zhang C; Xu X; Wang T; Lu Y; Lu Z; Wang T; Pan Z
Sci Rep; 2024 Apr; 14(1):7941. PubMed ID: 38575639
[TBL] [Abstract][Full Text] [Related]
12. Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder.
Christoph F; Weikert S; Kempkensteffen C; Krause H; Schostak M; Miller K; Schrader M
Int J Cancer; 2006 Sep; 119(6):1396-402. PubMed ID: 16642478
[TBL] [Abstract][Full Text] [Related]
13. Methylation patterns of Rb1 and Casp-8 promoters and their impact on their expression in bladder cancer.
Malekzadeh K; Sobti RC; Nikbakht M; Shekari M; Hosseini SA; Tamandani DK; Singh SK
Cancer Invest; 2009 Jan; 27(1):70-80. PubMed ID: 19160091
[TBL] [Abstract][Full Text] [Related]
14. OASIS/CREB3L1 is epigenetically silenced in human bladder cancer facilitating tumor cell spreading and migration in vitro.
Rose M; Schubert C; Dierichs L; Gaisa NT; Heer M; Heidenreich A; Knüchel R; Dahl E
Epigenetics; 2014 Dec; 9(12):1626-40. PubMed ID: 25625847
[TBL] [Abstract][Full Text] [Related]
15. Protein expression and gene promoter hypermethylation of CD99 in transitional cell carcinoma of urinary bladder.
Xuan Y; Kim S; Lin Z
J Cancer Res Clin Oncol; 2011 Jan; 137(1):49-54. PubMed ID: 20217126
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of glutathione S-transferase pi 1 expression and gene promoter methylation in Moroccan patients with urothelial bladder cancer.
Hadami K; Dakka N; Bensaid M; El Ahanidi H; Ameur A; Chahdi H; Oukabli M; Al Bouzidi A; Attaleb M; El Mzibri M
Mol Genet Genomic Med; 2018 Sep; 6(5):819-827. PubMed ID: 30043549
[TBL] [Abstract][Full Text] [Related]
17. Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status.
Maas S; Warskulat U; Steinhoff C; Mueller W; Grimm MO; Schulz WA; Seifert HH
Urology; 2004 Feb; 63(2):392-7. PubMed ID: 14972509
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic inactivation of ITIH5 promotes bladder cancer progression and predicts early relapse of pT1 high-grade urothelial tumours.
Rose M; Gaisa NT; Antony P; Fiedler D; Heidenreich A; Otto W; Denzinger S; Bertz S; Hartmann A; Karl A; Knüchel R; Dahl E
Carcinogenesis; 2014 Mar; 35(3):727-36. PubMed ID: 24265292
[TBL] [Abstract][Full Text] [Related]
19. Methylomics analysis identifies ZNF671 as an epigenetically repressed novel tumor suppressor and a potential non-invasive biomarker for the detection of urothelial carcinoma.
Yeh CM; Chen PC; Hsieh HY; Jou YC; Lin CT; Tsai MH; Huang WY; Wang YT; Lin RI; Chen SS; Tung CL; Wu SF; Chang DC; Shen CH; Hsu CD; Chan MW
Oncotarget; 2015 Oct; 6(30):29555-72. PubMed ID: 26320192
[TBL] [Abstract][Full Text] [Related]
20. Aberrant promoter hypermethylation of the CHFR gene in oral squamous cell carcinomas.
Baba S; Hara A; Kato K; Long NK; Hatano Y; Kimura M; Okano Y; Yamada Y; Shibata T
Oncol Rep; 2009 Nov; 22(5):1173-9. PubMed ID: 19787237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
